<DOC>
	<DOCNO>NCT01804140</DOCNO>
	<brief_summary>This screening study detect BRAF V600 mutation-positive patient enrollment clinical research study Zelboraf ( vemurafenib ) . Tumor sample collect analyzed eligible patient solid tumor ( metastatic melanoma papillary thyroid cancer ) multiple myeloma . All institution identify patient define screen protocol potential access separate vemurafenib protocol MO28072 .</brief_summary>
	<brief_title>A Screening Study Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies Zelboraf ( Vemurafenib )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<criteria>Histologically confirm solid tumor ( exclude melanoma papillary thyroid cancer ) multiple myeloma refractory standard therapy standard curative therapy exist consider appropriate investigator Patients multiple myeloma must receive least one line prior systemic therapy treatment multiple myeloma Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; 2 Uncontrolled concurrent malignancy Active untreated CNS metastasis History know carcinomatous meningitis Prior treatment BRAF MEK inhibitor ( prior sorafenib allow ) Uncontrolled , severe medical illness condition define protocol MO28072</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>